Expiration Date: January 12, 2017
Media: Internet - based
This activity focuses on soft tissue sarcoma (STS), and features a series of short video interviews with leading experts who address a variety of questions commonly faced by practicing community oncologists. The content and interviews are based on presentations given at Breakthroughs in Soft Tissue Sarcoma: Perspectives on Emerging Strategies, a CME-certified, ancillary satellite symposium of the Annual Sarcoma Meeting held in Salt Lake City, Utah.
CME Activity Table of Contents
- Recent Advances in Frontline Therapy for Metastatic and Unresectable STS
- Recent Advances in the Treatment of Metastatic and Unresectable STS Beyond Progression
- Sequencing of Newer Versus Older STS Therapies
- Emerging Options for Metastatic/Unresectable STS
- The Importance of Collaboration Between Academic and Community Cancer Care
Instructions For This Activity & Receiving Credit
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, and researchers interested in the treatment of STS. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with sarcoma may also participate.
At the conclusion of this activity, you should be better prepared to:
- Discuss contemporary multidisciplinary strategies utilized in the management of advanced forms of STS
- Explain novel mechanistic approaches under investigation for the treatment of patients with metastatic or unresectable STS
- Evaluate emerging clinical trial results in the context of evolving treatment paradigms in STS and multimodality sequencing in multiple lines of care
Faculty, Staff, and Planners' Disclosures
George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Robin L. Jones, BSc, MB, MRCP, MD (Res)
Royal Marsden Hospital
Team Leader, Sarcoma Clinical Trials
Institute of Cancer Research
William D. Tap, MD
Chief, Sarcoma Medical Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®
The following individuals have relevant financial relationships with commercial interests to disclose:
George D. Demetri, MD - Consultant: Bayer, Novartis, Pfizer, Lilly, EMD-Serono, Sanofi Oncology, Janssen Oncology, PharmaMar, GlaxoSmithKline, Daiichi-Sankyo, Ariad, AstraZeneca, WIRB-Copernicus Group, ZIOPHARM Oncology, Polaris; Research Support (to Dana-Farber for specific clinical trial agreements in Sarcoma Unit: Bayer, Novartis, EMD-Serono, Sanofi Oncology, Janssen Oncology, GlaxoSmithKline; Patent licensed to Novartis from Dana-Farber (royalty paid to Dana-Farber); Consultant, Scientific Advisory Board, Equity (minor stake, nonpublic): Kolltan Pharmaceuticals; Board of Directors, Scientific Advisory Board and Equity (minor stake, nonpublic): Blueprint Medicines; Consultant, Scientific Advisory Board/Equity (minor stake, nonpublic): G1 Therapeutics and Caris Life Sciences; Consultant, Scientific Advisory Board (>$10,000, <$20,000 and Equity (minor stake, nonpublic): Champions Oncology; Consultant, uncompensated, Equity (minor stake, nonpublic): Bessor Pharma; Robin L. Jones, BSc, MB, MRCP, MD (Res) - Consultant: Blueprint, Daiichi Sankyo, Adaptimmune, Immune Design, Eisai, Pharmamar, Merck, Serono, Eli Lilly, Immodulon; William D. Tap, MD - Consultant: Daiichi-Sankyo, Eli Lilly, EMD Serono, Plexxikon, Novartis; Grant/Research Support: Sarcoma Foundation of America, Threshold Pharmaceuticals; Other: Morphotek-IDMC Chair.
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise